(firstQuint)Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers.

 Single oral doses of AKB-4924 will be investigated in up to 6 sequential cohorts of 8 healthy male subjects.

 Primarily 6 dose levels are planned; the proposed doses are 20 mg, 60 mg, 120 mg, 240 mg, 360 mg, and 480 mg.

 Actual doses may be decreased or increased based on the safety and tolerability of the drug, as determined by the Investigator and Sponsor.

 Additional cohorts may be added as needed to test lower, higher, or repeat doses.

.

 Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers@highlight

This will be a double-blind, randomized, placebo-controlled, single ascending dose, Phase I study in healthy male subjects.

